|
1) Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998; 339: 69-75
|
|
|
|
2) Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 dia-betes. N Engl J Med. 2003; 348: 2285-93
|
|
|
|
|
|
3) Araki S, Haneda M, Sugimoto T, et al. Factors associated with frequent remission of micro-albuminuria in patients with type 2 diabetes. Diabetes. 2005; 54: 2983-7
|
|
|
|
|
|
4) Araki S, Haneda M, Koya D, et al. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes. 2007; 56: 1727-30
|
|
|
|
|
|
5) Shiga Microalbuminuria Reduction Trial (SMART) Group. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Micro-albuminuria Reduction Trial (SMART). Diabetes Care. 2007; 30: 1581-3
|
|
|
|
|
|
6) Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007; 30: 1577-8
|
|
|
|
|
|
7) Makino H, Haneda M, Babazono T, et al. Micro-albuminuria reduction with telmisartan in normo-tensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertens Res. 2008; 31: 657-64
|
|
|
|
|
8) Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008; 358: 2433-46
|
|
|
|
|
|
9) Sjolie A, Klein R, Porta M, et al, for the DIRECT programme study group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008; 372: 1385-93
|
|
|
|
|
|
10) Kawasumi M, Tanaka Y, Uchino H, et al. Strict glycemic control ameliorates the increase of carotid IMT in patients with type 2 diabetes. Endocr J. 2006; 53: 45-50
|
|
|
|
|
11) Baguet JP, Asmar R, Valensi P, et al. Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. Vasc Health Risk Manag. 2009; 5: 175-83
|
|
|
|
|
|
12) Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol. 2008; 52: 2198-205
|
|
|
|
|
|
13) Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366: 1279-89
|
|
|
|
|
|
14) Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thick-ness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation. 2005; 111: 2525-31
|
|
|
|
|
|
15) Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006; 296: 2572-81
|
|
|
|
|
|
16) Park SW, Kim SK, Cho YW, et al. Insulin resistance and carotid atherosclerosis in patients with type 2 diabetes. Atherosclerosis. 2009; 205: 309-13
|
|
|
|
|
|
17) Davidson M, Meyer PM, Haffner S, et al. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation. 2008; 117: 2123-30
|
|
|
|
|
|
18) Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008; 299: 1561-73
|
|
|
|
|
|
19) Nakayama T, Komiyama N, Yokoyama M, et al. Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: A randomized prospective study using intra-vascular ultrasound. Int J Cardiol. 2008 Sep 23. [Epub ahead of print]
|
|
|
|
|
|
20) Clementi F, Di Luozzo M, Mango R, et al. Regression and shift in composition of coronary atherosclerotic plaques by pioglitazone: insight from an intravascular ultrasound analysis. J Cardiovasc Med(Hagerstown). 2009; 10: 231-7
|
|
|
|
|